Diethyl 2-Propyl-1H-Imidazole-4,5-Dicarboxylate CAS 144689-94-1 Pite > 99.0% (HPLC) Olmesartan Medoxomil Faktori Entèmedyè
Pwovizyon chimik Ruifu Olmesartan Medoxomil Entèmedyè ak kalite siperyè:
4,5-Dimethyl-1,3-Dioxol-2-One (DMDO) CAS 37830-90-3
4-Chloromethyl-5-Methyl-1,3-Dioxol-2-One (DMDO-Cl) CAS 80841-78-7
Etil 4-(1-Idroksi-1-Methylethyl)-2-Propyl-Imidazol-5-Carboxylate CAS 144689-93-0
Dyetil 2-Propyl-1H-Imidazol-4,5-Dicarboxylate CAS 144689-94-1
Trityl Olmesartan Ethyl Ester CAS 144690-33-5
Trityl Olmesartan Asid CAS 761404-85-7
N2-Trityl Olmesartan Asid CAS 752179-89-8
Trityl Olmesartan Medoxomil CAS 144690-92-6
Olmesartan Medoxomil CAS 144689-63-4
Non Chimik | Dyetil 2-Propyl-1H-Imidazol-4,5-Dicarboxylate |
Sinonim | Dyetil 2-PropylImidazoledicarbonate;2-Propyl-1H-Imidazol-4,5-Dicarboxylic Asid Diethyl Ester;2-Propylimidazoledicarboxylic Asid Diethyl Ester |
Nimewo CAS | 144689-94-1 |
Nimewo CAT | RF-PI1872 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C12H18N2O4 |
Pwa molekilè | 254.29 |
Dansite | 1.160±0.06 g/cm3 |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Pale jòn poud blan poud |
Pite / Metòd analiz | >99.0% (HPLC) |
Pwen k ap fonn | 83.0 ~ 88.0 ℃ |
Kontni dlo (KF) | <0.50% |
Rezid sou ignisyon | <0.20% |
Maksimòm sèl enpurte | <0.50% |
Enpurte total | <1.00% |
Spectre proton RMN | Konfòm ak estrikti |
Tès Creole | Enterprise Standard |
Itilizasyon | Entèmedyè nan Olmesartan Medoxomil (CAS: 144689-63-4) |
Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite
Diethyl 2-Propyl-1H-Imidazole-4,5-Dicarboxylate (CAS: 144689-94-1) se yon entèmedyè nan sentèz Olmesartan Medoxomil (CAS: 144689-63-4).Olmesartan Medoxomil endike pou tretman tansyon wo (tansyon wo).Bese tansyon wo ede anpeche kou, atak kè, ak pwoblèm ren.Olmesartan fè pati yon klas dwòg ki rele anjyotansin reseptè blockers (ARB).Olmesartan travay pa detann veso sangen yo pou san ka koule pi fasil.Li ka itilize pou kont li oswa nan konbinezon ak lòt ajan antihypertansive.US Food and Drug Administration (FDA) te detèmine ke benefis Benicar kontinye depase risk potansyèl li yo lè yo itilize pou tretman pasyan ki gen tansyon wo dapre etikèt dwòg la.